The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)

UnknownOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

March 21, 2019

Primary Completion Date

March 12, 2024

Study Completion Date

March 12, 2024

Conditions
Cancer, All TypesCancer of LiverCancer of StomachCancer of Head and NeckCancer of RectumCancer of KidneyCancer of EsophagusCancer of ColonCancer SkinCancer of CervixCancer, MetastaticCancer of LarynxCancer of NeckCancer of LungCancer of Brain and Nervous SystemCancer of Vulva, DisseminatedCancer of PancreasSarcomaGISTSmall-cell Lung CancerAdenocarcinoma LungCancer of ProstateCancer, AdvancedAdrenal CancerTesticular CancerUterine CancerBronchoalveolar Cell Lung CancerCancer Unknown PrimaryGlioblastoma MultiformeOligodendrogliomaBreast CancerRenal Cell CarcinomaHepatocellular CarcinomaCholangiocarcinomaSquamous Cell CarcinomaTransitional Cell CarcinomaCancer, OtherCancer, AnalMelanomaCancer, Bile DuctCancer, BladderCancer Cords VocalCancers Cell NeuroendocrineCancer Differentiated PoorlyCancer, Anaplastic Thyroid
Trial Locations (1)

30501

RECRUITING

Specicare, Gainesville

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Georgia Institute of Technology

OTHER

collaborator

Predictive Oncology

UNKNOWN

collaborator

University of Washington

OTHER

collaborator

Netnoids

UNKNOWN

collaborator

Northeast Georgia Hospital System

UNKNOWN

lead

SpeciCare

INDUSTRY

NCT03896958 - The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology) | Biotech Hunter | Biotech Hunter